Form 4: Teva EVP Daniell Sells Shares Post-RSU Vesting

Richard Daniell, Teva's EVP, Europe Commercial, sold ordinary shares on March 3, 2026, following the vesting of restricted share units, including shares to cover tax obligations.

Summary

• Richard Daniell, Executive Vice President, Europe Commercial of Teva Pharmaceutical Industries Ltd. (TEVA), reported transactions on March 3, 2026.
• Daniell acquired 62,250 ordinary shares through the vesting of restricted share units (RSUs) granted on March 3, 2023.
• Following this acquisition, Daniell sold 62,250 ordinary shares at a weighted average price of $32.3599 per share, with prices ranging from $31.72 to $32.865.
• The sale of 62,250 shares included shares to cover tax withholding obligations and all vested shares from this specific RSU grant.
• Daniell also acquired 141,478 ordinary shares from performance-based RSUs that were earned on January 27, 2026, and vested on March 3, 2026.
• Subsequently, Daniell sold 66,735 ordinary shares, also at a weighted average price of $32.3599 per share, to cover tax withholding obligations related to the vesting of performance-based RSUs.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Daniell on November 10, 2025.
• After these transactions, Daniell directly beneficially owns 123,127 ordinary shares.
• A remaining 62,253 restricted share units from the March 3, 2023 grant are scheduled to vest on March 4, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It details routine executive compensation management and does not provide new information regarding the company's operational or financial performance.

Positives

• The vesting of restricted share units indicates the successful maturation of executive long-term incentive compensation plans.
• The transactions were pre-planned under a Rule 10b5-1 trading plan, demonstrating structured and compliant management of equity compensation.

Negatives

• The sale of ordinary shares by an executive, even for tax purposes, reduces their direct ownership stake in the company.

Risks

• The value of the executive's remaining equity holdings is subject to market fluctuations of Teva's ordinary shares.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on past executive compensation transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
• Sales represent shares vested, including shares to cover tax withholding obligations in connection with the vesting of restricted share units.

Industry Context

StockSavvy.ai notes that executive transactions involving the vesting and subsequent sale of restricted share units are a common and routine aspect of executive compensation programs across various industries, particularly for managing tax liabilities associated with equity awards.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Rule 10b5-1 trading plans for pre-scheduled sales of executive equity compensation is a widely adopted best practice in corporate governance, aligning with industry standards for transparency and mitigating insider trading concerns.
• The practice of selling a portion of vested shares to cover tax withholding obligations is standard across publicly traded companies globally, ensuring executives meet their tax liabilities upon the realization of equity income.

Stakeholder Impact

• Shareholders may observe the executive's management of their equity compensation, which is a standard part of executive remuneration and does not typically indicate a change in company fundamentals.

Next Steps

• The remaining 62,253 restricted share units from the March 3, 2023 grant are scheduled to vest on March 4, 2027.

Key Dates

Recommendation

The Form 4 filing details routine executive compensation management, specifically the vesting and subsequent sale of shares to cover tax obligations and monetize vested restricted share units. These transactions are pre-scheduled under a 10b5-1 plan and do not reflect a discretionary change in the executive's view of the company's prospects. Therefore, it does not provide new information warranting a change in investment recommendation based solely on this filing.

Keywords

Teva Pharmaceutical Industries, TEVA, Richard Daniell, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Executive Compensation, Stock Sale, 10b5-1 Plan